Prospective evaluation of the International Neuroblastoma Staging System (INSS) and the International Neuroblastoma Response Criteria (INRC) in a multicentre setting

Castel, Victoria; Garcı́a-Miguel, P; Cañete, Adela; Melero, Carmen; Navajas, A.; Ruiz-Jiménez, J.I.; Navarro, Samuel; Badal, Madan

doi:10.1016/s0959-8049(98)00395-5

Cited by 29 publications

(22 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Neuroblastoma is postsurgically staged using the International Neuroblastoma Staging System: stage 1 (localized tumor with complete gross excision), stage 2 (localized tumor with incomplete gross excision or ipsilateral tumor involvement), stage 3 (unresectable unilateral tumor infiltrating the midline), stage 4 (distant metastases), or stage 4S (special) (localized primary tumor with metastases confined to the skin, liver, and bone marrow in a patient b1 year of age) [5,[20][21][22]. Staging helps determine 5-year survival: stage 1 (92%), stage 2 (78%), stage 3 (75%), stage 4 (33%-73%), and stage 4S (60%-90%) [5,20,21]. Independent of stage, N-myc nonamplification, favorable histology, and age less than 1 year at diagnosis improve prognosis [5].…”

Section: Discussionmentioning

confidence: 99%

Metastatic neuroblastoma mimicking infantile hemangioma

Hassanein

Fishman

Mulliken

et al. 2010

Journal of Pediatric Surgery

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Metastatic neuroblastoma mimicking infantile hemangioma

Hassanein

Fishman

Mulliken

et al. 2010

Journal of Pediatric Surgery

View full text Add to dashboard Cite

“…In early-phase clinical trials, RECIST is the most common approach to assessment of response; however, RECIST does not address the most frequent sites of recurrent neuroblastoma, bone and bone marrow 3 . The International Neuroblastoma Response Criteria (INRC) include bone marrow and bone disease 4,5 , albeit not well quantified by INRC criteria, leading to variation in interpretation of disease burden and potential poor correlation with the true disease state.…”

Section: Introductionmentioning

confidence: 99%

Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials

London

Bagatell

Weigel

et al. 2017

Cancer

127

View full text Add to dashboard Cite

Background Early-phase trials in relapsed neuroblastoma patients historically used objective “response” of measureable disease (RECIST, without bone/bone marrow assessment) to select agents for further study. Historical cohorts may be small and potentially biased; relapse studies from international registries are outdated. Using our large recent cohort of relapsed/refractory neuroblastoma patients from COG modern-era early-phase trials, we determined outcome and quantified parameters for designing future studies. Methods The first early-phase COG trial enrollment (sequential) of 383 distinct relapsed/refractory neuroblastoma patients on 23 Phase 1, 3 Phase 1/2, and 9 Phase 2 trials (8/2002–1/2014) was analyzed for progression-free survival (PFS), overall survival (OS), and time-to-progression (TTP). High-risk neuroblastoma planned frontline therapy included hematopoietic stem cell transplant (~two-thirds received ≥1 HSCT); 13.2% received dinutuximab. Results From time of patient’s first early-phase trial enrollment (n=383): 1-year/4-year PFS were 21±2%/6±1%; 1-year/4-year OS were 57±3%/20±2%, respectively; median TTP was 58 days (interquartile range: 31–183 days, n=350); median follow-up was 25.3 months (n=33 without relapse/progression). Median time from diagnosis to first relapse/progression (TTFR) was 18.7 months (range: 1.4–64.8 months) (n=176). MYCN amplification (p=0.003, p<0.0001) and 11q LOH (p=0.02, p=0.03) were prognostic of worse PFS and OS, respectively, after early-phase trial enrollment. Conclusions This recent COG relapsed/refractory neuroblastoma cohort is inclusive and representative. This is the first meta-analysis of PFS/TTP/OS in the context of modern therapy. These results will inform design of future phase 2 studies by providing: historical context during the search for more effective agents, and factors prognostic of PFS/OS after relapse to stratify randomization.

show abstract

“…They have a pronounced tendency to spread through the bloodstream and involve the liver, lungs, bone marrow and bones. The International Neuroblastoma Staging System includes following stadia: 1, 2A and 2B, 3, 4 and 4S [10,12]. The first one (with the localised tumour removed in toto) stadia 2A and 2B (localised tumour with incomplete gross resection but non-adherent to lymph nodes) as well as the stadium 4S (localised tumour, as defined for stadia 1 and 2, with dissemination limited to skin or liver or bone marrow in children < 1 yr) [13,14] are relatively rare in clinical practice in Poland.…”

Section: Introductionmentioning

confidence: 99%

“…The first one (with the localised tumour removed in toto) stadia 2A and 2B (localised tumour with incomplete gross resection but non-adherent to lymph nodes) as well as the stadium 4S (localised tumour, as defined for stadia 1 and 2, with dissemination limited to skin or liver or bone marrow in children < 1 yr) [13,14] are relatively rare in clinical practice in Poland. The most common are stadium 3 (malignancy involving the surrounding lymphatic nodes) and stadium 4 (like the previous one but with distant metastases) [12].…”

Section: Introductionmentioning

confidence: 99%

Vascular endothelial growth factor (VEGF)-C - a potent risk factor in children diagnosed with stadium 4 neuroblastoma.

Nowicki¹,

Konwerska²,

Ostalska‐Nowicka³

et al. 2009

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

Abstract:To evaluate the immunohistochemical expression of VEGF-C, CD34 and VEGFR-2 in cancer tissue of children diagnosed with stadium 4 neuroblastoma (NB) and correlate their presence with the survival rate of children diagnosed with that stage of the disease. Eighteen children assigned to stadium 4 composed the study group. Fourteen patients (allocated to stadium 3) formed a control group. VEGF-C, CD34 and VEGFR-2 expressions were evaluated by immunohistochemical assay. Consecutive slides incubated with anti-CD34 and anti-VEGFR-2 antibodies revealed that the two markers were colocalized within endothelial layer of the blood vessels. On the other hand, VEGF-C was expressed exclusively in tumour cells. As demonstrated by Fisher's exact test, the risk of NB treatment failure (progression or relapse) as well as tumour related death, when all the patients were considered, was found to be significant in VEGF-C positive patients. VEGF-C expression in NB constitutes a potent risk factor and may direct future anti-angiogenic treatment strategy. The proximity of VEGF-C and CD34/VEGFR-2 of NB could be the equivalent of a potentially interesting VEGF-C fashion involving a tumour cell invasion into the blood vessels in an early phase of metastases promoting.

show abstract

Prospective evaluation of the International Neuroblastoma Staging System (INSS) and the International Neuroblastoma Response Criteria (INRC) in a multicentre setting

Cited by 29 publications

References 15 publications

Metastatic neuroblastoma mimicking infantile hemangioma

Metastatic neuroblastoma mimicking infantile hemangioma

Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials

Vascular endothelial growth factor (VEGF)-C - a potent risk factor in children diagnosed with stadium 4 neuroblastoma.

Contact Info

Product

Resources

About